Effects of Marijuana on Symptoms of OCD

• Status: Completed
• Trial end date: 2020-10-29
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this pilot research study is to test whether certain components of the marijuana plant, known as "cannabinoids", may help to reduce symptoms in patients with OCD. Specifically, patients enrolled in the study will smoke marijuana containing different concentrations of 2 different cannabinoids, THC and CBD. Both of these agents act on the brain's "endocannabinoid system," which has been hypothesized to play a role in OCD. Neither compound is currently FDA-approved for treating OCD.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York State Psychiatric Institute

Criteria

Inclusion Criteria:

• Age 21-55

• Physically healthy

• Diagnosed with OCD

• Current marijuana user

• Women of childbearing potential must be using an effective form of birth control

• Not currently taking psychotropic medications

• Ability to provide informed consent

Exclusion Criteria:

• History of any significant medical condition that may increase the risk of participation

• Females who are pregnant or nursing

• If female, not pregnant

• Current or lifetime history of psychiatric disorders other than OCD that may increase the risk of participation

• Current substance use disorder

• Severe depression or positive urine toxicology (other than THC) at screening, or any adverse reaction to a cannabinoid

• Patients who are seeking treatment for substance abuse

• Patients who are planning to begin a course of cognitive-behavioral therapy within 8 weeks of beginning the study